202 related articles for article (PubMed ID: 22929054)
21. Actual antibiotic resistance pattern of Brucella melitensis in central Anatolia. An update from an endemic region.
Tanyel E; Coban AY; Koruk ST; Simsek H; Hepsert S; Cirit OS; Tulek N
Saudi Med J; 2007 Aug; 28(8):1239-42. PubMed ID: 17676210
[TBL] [Abstract][Full Text] [Related]
22. Biotypes and antimicrobial susceptibilities of Brucella isolates.
Bodur H; Balaban N; Aksaray S; Yetener V; Akinci E; Colpan A; Erbay A
Scand J Infect Dis; 2003; 35(5):337-8. PubMed ID: 12875523
[TBL] [Abstract][Full Text] [Related]
23. In vitro antibacterial activity of tigecycline in comparison with doxycycline, ciprofloxacin and rifampicin against Brucella spp.
Turan H; Arslan H; Azap OK; Serefhanoğlu K; Uncu H
Int J Antimicrob Agents; 2007 Aug; 30(2):186-7. PubMed ID: 17462865
[No Abstract] [Full Text] [Related]
24. Antimicrobial susceptibility of Brucella melitensis isolates in Peru.
Maves RC; Castillo R; Guillen A; Espinosa B; Meza R; Espinoza N; Núñez G; Sánchez L; Chacaltana J; Cepeda D; González S; Hall ER
Antimicrob Agents Chemother; 2011 Mar; 55(3):1279-81. PubMed ID: 21199926
[TBL] [Abstract][Full Text] [Related]
25. Molecular epidemiological and antibiotic susceptibility characterization of Brucella isolates from humans in Sicily, Italy.
Marianelli C; Graziani C; Santangelo C; Xibilia MT; Imbriani A; Amato R; Neri D; Cuccia M; Rinnone S; Di Marco V; Ciuchini F
J Clin Microbiol; 2007 Sep; 45(9):2923-8. PubMed ID: 17634297
[TBL] [Abstract][Full Text] [Related]
26. In vitro antimicrobial susceptibility of Brucella species.
Baykam N; Esener H; Ergönül O; Eren S; Celikbas AK; Dokuzoguz B
Int J Antimicrob Agents; 2004 Apr; 23(4):405-7. PubMed ID: 15081093
[TBL] [Abstract][Full Text] [Related]
27. Reduced Susceptibility to Rifampicin and Resistance to Multiple Antimicrobial Agents among Brucella abortus Isolates from Cattle in Brazil.
Barbosa Pauletti R; Reinato Stynen AP; Pinto da Silva Mol J; Seles Dorneles EM; Alves TM; de Sousa Moura Souto M; Minharro S; Heinemann MB; Lage AP
PLoS One; 2015; 10(7):e0132532. PubMed ID: 26181775
[TBL] [Abstract][Full Text] [Related]
28. Proteomics-based screening and antibiotic resistance assessment of clinical and sub-clinical Brucella species: An evolution of brucellosis infection control.
Elbehiry A; Aldubaib M; Al Rugaie O; Marzouk E; Abaalkhail M; Moussa I; El-Husseiny MH; Abalkhail A; Rawway M
PLoS One; 2022; 17(1):e0262551. PubMed ID: 35025975
[TBL] [Abstract][Full Text] [Related]
29. Molecular characterization and antimicrobial susceptibility testing of clinical and non-clinical
Wareth G; El-Diasty M; Abdel-Hamid NH; Holzer K; Hamdy MER; Moustafa S; Shahein MA; Melzer F; Beyer W; Pletz MW; Neubauer H
One Health; 2021 Dec; 13():100255. PubMed ID: 34027005
[TBL] [Abstract][Full Text] [Related]
30. MLVA typing and antibiotic susceptibility of Brucella human isolates from Liaoning, China.
Jiang H; Mao LL; Zhao HY; Li LY; Piao DR; Yao WQ; Cui BY
Trans R Soc Trop Med Hyg; 2010 Dec; 104(12):796-800. PubMed ID: 20832094
[TBL] [Abstract][Full Text] [Related]
31. [Short communication: Investigation of in vitro antibiotic susceptibility of Brucella melitensis].
Alişkan H; Turunç T; Demiroğlu YZ; Colakoğlu S; Arslan H
Mikrobiyol Bul; 2008 Jan; 42(1):125-9. PubMed ID: 18444570
[TBL] [Abstract][Full Text] [Related]
32. [In vitro sensitivity to five antibiotics of clinical isolated Brucella spp].
Efron A; Lopardo H; Lucero NE
Rev Argent Microbiol; 1999; 31 Suppl 1():56-7. PubMed ID: 10509415
[No Abstract] [Full Text] [Related]
33. Susceptibility of Brucella melitensis to fluoroquinolones.
Qadri SM; Akhtar M; Ueno Y; al-Sibai MB
Drugs Exp Clin Res; 1989; 15(10):483-5. PubMed ID: 2632216
[TBL] [Abstract][Full Text] [Related]
34. Genetic bases of the rifampin resistance phenotype in Brucella spp.
Marianelli C; Ciuchini F; Tarantino M; Pasquali P; Adone R
J Clin Microbiol; 2004 Dec; 42(12):5439-43. PubMed ID: 15583262
[TBL] [Abstract][Full Text] [Related]
35. Epidemiological survey of rifampicin resistance in clinic isolates of Brucella melitensis obtained from all regions of Turkey.
Sayan M; Kılıc S; Uyanık MH
J Infect Chemother; 2012 Feb; 18(1):41-6. PubMed ID: 21826587
[TBL] [Abstract][Full Text] [Related]
36. Antibacterial activity of lomefloxacin against Brucella melitensis.
Qadri SM; al-Sedairy S; Ueno Y
Diagn Microbiol Infect Dis; 1990; 13(3):277-9. PubMed ID: 2383977
[TBL] [Abstract][Full Text] [Related]
37. Failure of a short-term antibiotic therapy for human brucellosis using ciprofloxacin. A study on in vitro susceptibility of Brucella strains.
Al Dahouk S; Hagen RM; Nockler K; Tomaso H; Wittig M; Scholz HC; Vergnaud G; Neubauer H
Chemotherapy; 2005 Oct; 51(6):352-6. PubMed ID: 16227689
[TBL] [Abstract][Full Text] [Related]
38. Identification, Genotyping and Antimicrobial Susceptibility Testing of
Khan AU; Shell WS; Melzer F; Sayour AE; Ramadan ES; Elschner MC; Moawad AA; Roesler U; Neubauer H; El-Adawy H
Microorganisms; 2019 Nov; 7(12):. PubMed ID: 31766725
[TBL] [Abstract][Full Text] [Related]
39. Investigation of antibiotic susceptibilities of Brucella Strains isolated from various clinical samples in eastern Turkey.
Gültekin E; Uyanık MH; Albayrak A; Kılıç S
Eur J Med Res; 2021 Jun; 26(1):57. PubMed ID: 34134763
[TBL] [Abstract][Full Text] [Related]
40. Dual versus triple therapy for uncomplicated brucellosis: A retrospective cohort study.
Al-Madfaa RO; Alalawi MA; Basudan LO; Alhejaili SF; Eljaaly K; Madani TA; Thabit AK
J Infect Dev Ctries; 2020 Dec; 14(12):1380-1386. PubMed ID: 33378279
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
